CD28 TCE

N/A

Report date: 2026/03/19 16:59:33

Base Information

Drug NameCD28 TCE
Drug Alias NameAnti-CD28/anti-B7-H3 bispecific T-cell engager prodrug (Adagene Suzhou)Anti-CD28/anti-HER2 bispecific T-cell engager prodrug (Adagene Suzhou)Anti-CD28/anti-TROP2 bispecific T-cell engager prodrug (Adagene Suzhou)Anti-CD28/anti-TAA bispecific T-cell engager prodrug (Adagene Suzhou)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCD276 antigen modulatorsT-cell-specific surface glycoprotein CD28 agonistsTumor-associated calcium signal transducer 2 modulators +[4] 
TargetsTumor-associated calcium signal transducer 2T-cell-specific surface glycoprotein CD28CD276 antigen +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAdagene (Suzhou) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAdagene (Suzhou) Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A